SCHEMBL4680640

SCHEMBL4680640

O=C(O)C(O)=CC(=O)c1csc(Cc2ccc(F)cc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
NPC1 O15118 2/20 0.55
GAA P10253 2/20 0.55
LMNA P02545 6/20 0.50
MAPT P10636 6/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MMP1 P03956 3/20 0.45
MMP13 P45452 3/20 0.45
MMP2 P08253 2/20 0.45
MMP9 P14780 2/20 0.45
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 3/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4680636 1.00 RAB9A (0.55) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4678169 0.88 HDAC1 (0.60) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4678174 0.88 HDAC1 (0.60) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4671451 0.87 HDAC1 (0.47) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4674190 0.87 HDAC1 (0.47) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4674184 0.87 HDAC1 (0.47) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4671457 0.87 HDAC1 (0.47) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4673304 0.86 HDAC1 (0.48) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4673302 0.86 HDAC1 (0.48) RAB9AL3MBTL1NPC1GAALMNA
SCHEMBL4677602 0.85 RAB9A (0.48) RAB9AL3MBTL1NPC1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 RAB9A 2021/4885L3MBTL1 1170/4885NPC1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.